Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPC-157 + TB-500
- Development stage
- Unknown
- Modality
- Peptides
- Administration
- Intramuscular, Subcutaneous
01
Overview
BPC-157 + TB-500 (commonly referred to as the "Wolverine stack" or "Wolverine blend") is a combination of two synthetic tissue-repair peptides: Body Protection Compound-157 (BPC-157) and TB-500 (a synthetic fragment of Thymosin Beta-4). BPC-157 is a pentadecapeptide derived from a protective protein found in human gastric juice, which is studied for its localized ability to promote angiogenesis, increase nitric oxide signaling, and accelerate the healing of tendons, ligaments, and gastrointestinal tissues. TB-500 is an acetylated seven-amino-acid fragment of thymosin beta-4 that acts systemically to regulate actin polymerization, thereby enhancing cell migration and tissue remodeling body-wide. The combination is widely sold online as a research-use-only (RUO) or compounded peptide blend for soft-tissue, tendon, and joint injury recovery, though it is not FDA-approved and lacks robust clinical trial data in humans.
- Other names
- BPC 157 + TB 500Wolverine BlendWolverine Stack
02
Targets
GHR (Growth hormone receptor)ActinNOS1 (nNOS)VEGFR2 (Vascular endothelial growth factor receptor 2)Actin filament proteins
Beyond the preview
Go deeper on BPC-157 + TB-500.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPC-157 + TB-500.